Plain-English reading on the vagus nerve, its science and how to look after it
Conditions

The Role of Vagus Nerve in Atrial Fibrillation: A Comprehensive Analysis

A flat folk-art vector illustration of a heart filled edge to edge with cornflowers, daisies and olive sprigs.


The vagus nerve has a complex and clinically important relationship with atrial fibrillation (AF) — the most common sustained cardiac arrhythmia, affecting an estimated 37 million people worldwide. Vagal activity can both trigger and terminate AF episodes, and this dual role has made the vagus nerve a target for emerging AF therapies. Understanding the vagal contribution to AF is essential for anyone with this condition or at risk of developing it.

The Vagal AF Trigger

A subset of AF is classified as “vagal AF” or “vagotonic AF” — episodes triggered by conditions that increase vagal tone. The classic presentation is AF that occurs at rest, during sleep, after large meals, or during the post-exercise recovery period (when vagal tone rebounds). This pattern contrasts with “adrenergic AF,” which occurs during exercise or emotional stress. Vagal AF accounts for an estimated 6-25 percent of paroxysmal AF episodes in studies, though the true prevalence may be higher because the triggering conditions are often not systematically recorded.

The mechanism involves the electrophysiological effects of vagal stimulation on the atria. Acetylcholine released by vagal nerve endings activates muscarinic M2 receptors on atrial cardiomyocytes, which open IKACh potassium channels. This shortens the atrial action potential duration and the atrial effective refractory period — the period during which the atrial muscle cannot be re-excited. When the refractory period is shortened, re-entrant electrical circuits can form more easily (the wavelength of the re-entrant circuit must be shorter than the available path length, and shorter refractory periods reduce the wavelength). Additionally, vagal stimulation increases the spatial dispersion of refractoriness across the atria — different areas recover excitability at different rates — which provides the electrical heterogeneity needed for re-entry to initiate.

The pulmonary veins are particularly important in vagal AF. The sleeves of atrial muscle that extend into the pulmonary veins are densely innervated by vagal fibres, and these sleeves are the most common source of ectopic beats that trigger AF. Vagal stimulation increases the spontaneous firing rate of pulmonary vein cardiomyocytes, providing more trigger beats in tissue that is already predisposed to arrhythmia.

The Vagal AF Terminator

Paradoxically, the vagus nerve can also terminate AF. Vagal stimulation slows conduction through the atrioventricular (AV) node, which does not terminate AF itself but reduces the ventricular rate (the heart rate the patient experiences) — this is the basis of the “vagal manoeuvres” (Valsalva, carotid sinus massage, cold water face immersion) used to slow a fast heart rate in AF. More importantly, emerging evidence suggests that vagal stimulation at specific parameters can reduce the inflammatory and electrophysiological substrate that maintains AF.

A landmark 2015 study by Stavrakis and colleagues (published in the Journal of the American College of Cardiology) showed that low-level transcutaneous vagus nerve stimulation (taVNS) at the tragus of the ear suppressed AF in patients undergoing cardiac surgery. The stimulation reduced inflammatory markers (C-reactive protein, TNF-alpha) and decreased AF burden in the post-operative period. This anti-inflammatory effect may reduce the atrial remodelling (fibrosis, inflammation, electrical remodelling) that maintains AF as a chronic condition.

A subsequent randomised trial (TREAT-AF, Stavrakis et al. 2020, also in JACC) showed that chronic taVNS over 6 months reduced AF burden (the percentage of time spent in AF) by approximately 75 percent in patients with paroxysmal AF compared to sham stimulation. The mechanism appeared to involve reduced atrial inflammation and autonomic remodelling — a shift from the sympathetic-dominant, pro-inflammatory state that maintains AF toward a more balanced autonomic profile.

Your local vagus nerve experts

Find a vagus nerve practitioner near you

Our directory lists 2,684 practitioners across the US, from polyvagal-informed therapists to HRV biofeedback clinics.

Or browse by approach

The directory covers the United States for now. Listings come from practitioners’ own websites and are not endorsements or medical advice. Browse the full directory.

How Both Effects Coexist

The apparent contradiction — vagal activity can both trigger and suppress AF — is explained by the difference between acute and chronic effects, and by the specific stimulation parameters. Acute, strong vagal surges (such as occur during vasovagal episodes, post-prandial vagal activation, or sleep) shorten atrial refractoriness and create the electrophysiological conditions for AF to initiate. Chronic, low-level vagal stimulation at specific parameters modulates the inflammatory and autonomic substrate, reducing the conditions that maintain AF over time.

The dose-response relationship also matters. High-intensity vagal stimulation (strong enough to produce bradycardia) is more likely to trigger AF through the refractoriness mechanism. Low-level stimulation below the bradycardia threshold (sub-threshold taVNS, as used in the TREAT-AF trial) appears to produce the anti-inflammatory and anti-remodelling effects without the pro-arrhythmic refractoriness changes.

Clinical Implications

For people with vagal AF. If AF episodes are triggered by rest, sleep, post-meal periods, or post-exercise recovery, the pattern suggests vagal AF. Management considerations include avoiding large meals (particularly high-fat meals that produce strong vagal activation), avoiding alcohol (which has both direct pro-arrhythmic effects and vagal effects), and potentially adjusting the timing of rate-control medications. Beta-blockers and calcium channel blockers — standard rate-control drugs — can worsen vagal AF by further enhancing vagal effects on the AV node. In vagal AF, flecainide or disopyramide (which has vagolytic properties) may be preferred pharmacological options.

For people with AF considering vagal training. The concern that breathing exercises, cold exposure, or other vagal techniques might trigger AF is reasonable but appears to be outweighed by the evidence for benefit. The TREAT-AF trial used low-level taVNS — a more direct vagal stimulus than breathing exercises — and showed AF reduction, not worsening. Breathing exercises and HRV biofeedback that improve baseline vagal tone and autonomic balance are likely beneficial for AF through anti-inflammatory and autonomic remodelling effects. However, intense acute vagal stimuli (prolonged cold face immersion, forceful Valsalva manoeuvres) should be approached cautiously by people with known vagal AF triggers, and any vagal training programme should be discussed with the treating cardiologist or electrophysiologist.

taVNS as an emerging AF therapy. Low-level taVNS is being investigated as both an adjunctive therapy for AF and as a potential alternative to antiarrhythmic drugs in selected patients. Clinical trials are ongoing, and taVNS is not yet a standard treatment for AF. However, the TREAT-AF results are among the most compelling clinical trial data for any non-invasive VNS application and have generated substantial interest in the electrophysiology community.

The vagus nerve’s role in atrial fibrillation illustrates the complexity of autonomic cardiac regulation — the same nerve that can trigger an arrhythmia may also hold the key to treating it. My Vagus Nerve & Me covers the full cardiac vagal story. Get My Vagus Nerve & Me eBook and understand how your vagus nerve shapes your heart rhythm.